ADVERTISEMENT

New effective treatment regimen for rifampicin-resistant tuberculosis

Heather Mason   |   Medical News   |   30 December 2022
ADVERTISEMENT

The regimen duration is half that of standard treatments.

Research supported by Médecins sans Frontières has found that a six-month treatment regimen of oral bedaquiline, pretomanid, linezolid, plus moxifloxacin (BPaLM) for treating rifampicin-resistant tuberculosis was not inferior to the accepted standard care treatment, with a better safety profile.

Patients 15 years...

          

Topic Challenges

left
right